ライフサイエンスコーパス: colistin

1 production of MCR-1 negated the efficacy of colistin.

2 edly reduces AKI risk, allowing safer use of colistin.

3 sent a major dose-limiting adverse effect of colistin.

4 lipid A modification mediates resistance to colistin.

5 pharmacological properties compared with CMS/colistin.

6 is not reduced by addition of rifampicin to colistin.

7 part to the inherent cationic properties of colistin.

8 emonstrating its stability in the absence of colistin.

9 aptability of A. baumannii to the antibiotic colistin.

10 l drugs such as tobramycin, tigecycline, and colistin.

11 ptible to colistin, and 14 were resistant to colistin.

12 infections, reviving interest in the use of colistin.

13 methyl ether (aaPEG) onto the Thr residue of colistin.

14 me that confers resistance to the antibiotic colistin.

15 dence interval [CI], .63-1.83) for high-dose colistin.

16 esistant gram-negative bacteria treated with colistin.

17 highly resistant to the last-line antibiotic colistin.

18 ere significantly more common with high-dose colistin.

19 s aeruginosa, including strains resistant to colistin.

20 C 25922l, the QC ranges were as follows: for colistin, 0.25 to 1 microg/ml (11 to 17 mm), and for pol

21 CC 27853, the QC ranges were as follows: for colistin, 0.25 to 2 microg/ml (11 to 17 mm), and for pol

22 Participants were randomized to receive colistin (1 million IU; n = 73) or placebo (0.45% saline

23 ntose phosphate pathway induced initially by colistin (15 min and 1 hr) and later by doripenem (4 hr)

24 easured using LC-MS following treatment with colistin (2 mg/L) or doripenem (25 mg/L) alone, and thei

25 ceptible or very major errors were noted for colistin (5%) and polymyxin B (6%).

26 the latter period, a new policy of high-dose colistin (9 million international units [MIU] loading do

27 ption of minocycline (79.1% susceptible) and colistin (98.8% susceptible).

28 In severely ill patients receiving colistin according to a PK/PD-driven dosing approach, ba

29 AKI risk in severely ill patients receiving colistin according to a recently proposed dosing strateg

30 Colistin adherence to plastics can be diminished by addi

31 Colistin administration was driven by a modified pharmac

32 nd some were less toxic than polymyxin B and colistin against mammalian HepG2 cells and human primary

33 ents were randomly allocated (1:1) to either colistin alone, 2 MU every 8 hours intravenously, or col

34 y of XDR A. baumannii infections compared to colistin alone.

35 ng reduced clinical toxicity associated with colistin, also known as polymyxin E, and improved target

36 ferent conventions used to describe doses of colistin; an absence of appropriate pharmacopoeial stand

37 on criteria, 144 were treated with high-dose colistin and 385 with lower-dose colistin regimens.

38 These results showed that colistin and amylase-activated dextrin-colistin conjugat

39 ion results in increased sensitivity to both colistin and cationic antimicrobial peptides of the inna

40 es per 100 patient-days ranged from 0.2 (for colistin and ceftazidime in P. aeruginosa and for carbap

41 e generated a propensity score for high-dose colistin and conducted propensity-adjusted multivariable

42 esponse did not differ significantly between colistin and control groups (OR, 1.14; 95% confidence in

43 In biological studies, both colistin and dextrin-colistin conjugate effectively inhi

44 the MDR-PA keratitis isolates was least for colistin and imipenem (56.52% each).

45 ion was 168 (65) versus 103 (37) days in the colistin and placebo groups, respectively (P = 0.038).

46 ion was 165 (42) versus 111 (52) days in the colistin and placebo groups, respectively (P = 0.11).

47 ted States where parenteral products of both colistin and polymyxin B are available, prospective stud

48 The polymyxin lipodecapeptides colistin and polymyxin B have become last resort therapi

49 Colistin and polymyxin B have indistinguishable microbio

50 evaluation of the antimicrobial activity of colistin and polymyxin B was initiated using 200 bloodst

51 e the key differences between parenteral CMS/colistin and polymyxin B, and highlight the clinical imp

52 was comparable (on a molar basis) to that of colistin and polymyxin B, with an even broader spectrum

53 bacteria, clinicians are increasingly using colistin and polymyxin B.

54 criteria for the testing of the polymyxins, colistin and polymyxin B.

55 tudy, we assessed whether the combination of colistin and rifampicin reduced the mortality of XDR A.

56 To understand the impact of banning colistin and the epidemiology of multi-drug-resistant (M

57 onsusceptible to all drug classes except for colistin and tigecycline, and standard combination thera

58 BrlR reciprocally contributed to colistin and tobramycin resistance in P. aeruginosa PAO1

59 The difference in susceptibility to colistin and tobramycin was eliminated by combination tr

60 Fourteen were susceptible to colistin, and 14 were resistant to colistin.

61 m therapy with a combination of tigecycline, colistin, and meropenem was associated with lower mortal

62 Polymyxins including colistin are an important "last-line" treatment for infe

63 Carbapenem and colistin are the last-resort antibiotics used for treati

64 2017, China will implement the withdrawal of colistin as a growth promoter, removing over 8,000 tonne

65 uated the efficacy and safety of aerosolized colistin as adjunctive therapy to i.v. antimicrobials or

66 everely limited and often require the use of colistin as drug of last resort.

67 alone, 2 MU every 8 hours intravenously, or colistin (as above), plus rifampicin 600 mg every 12 hou

68 Of 70 patients who received colistin at a median daily dose of 9 million IU (MIU; in

69 ethanesulfonate (CMS) is the only prodrug of colistin available for clinical use for the treatment of

70 with the maximum allowed daily dose of 360mg colistin base activity.

71 with the maximum allowed daily dose of 360mg colistin base activity.

72 ive was to determine if colistin dose (mg of colistin base activity/kg/day) independently predicts da

73 wide, and comparative prospective studies of colistin-based combination therapies are lacking, our ob

74 greater than 2 mg/L compared with the use of colistin-carbapenem (hazard ratio, 6.93; 95% CI, 1.61-29

75 istant A. baumannii bacteremia, treated with colistin-carbapenem and colistin-tigecycline combination

76 /11) and 100% (3/3) of patients treated with colistin-carbapenem and colistin-tigecycline, respective

77 s from this retrospective study suggest that colistin-carbapenem combinations may result in improved

78 r colistin-tigecycline group was 18% and for colistin-carbapenem group was 0% (p=0.059).

79 apy: colistin-tigecycline in 29 patients and colistin-carbapenem in 26.

80 ard combination therapy as use of parenteral colistin-carbapenem or colistin-tigecycline for at least

81 Treatment with a colistin-carbapenem regimen was an independent predictor

82 centration greater than 2 mg/L compared with colistin-carbapenem therapy for extensively drug-resista

83 listin-tigecycline versus patients receiving colistin-carbapenem were 35% versus 15% (p=0.105) and 69

84 oodstream CRGNIs at 2 of these hospitals met colistin case criteria.

85 The odds of in-hospital death among colistin cases (compared with discharge to home) decreas

86 Although the incidence of colistin cases nearly tripled within 7 years, more of th

87 The primary outcomes were the number of colistin cases per 100,000 admissions per year and chang

88 Colistin cases represent a severely ill population with

89 In a 4-hospital chart review, 81.6% of colistin cases were found to have culture-positive CRGNI

90 secutive days or died during therapy (termed colistin cases).

91 l of 5011 unique patients were identified as colistin cases.

92 Colistin caused early (15 min and 1 hr) disruption of th

93 The increase in colistin clearance when patients were on RRT was determi

94 ically desirable average steady-state plasma colistin concentration (Css,avg) of 2mg/L.

95 to determine the average steady-state plasma colistin concentration (Css,avg) that would be achieved

96 bility to achieve clinically relevant plasma colistin concentrations.

97 iological studies, both colistin and dextrin-colistin conjugate effectively inhibited LPS-induced hem

98 entration-dependent manner, but only dextrin-colistin conjugate showed no additive toxicity at higher

99 that colistin and amylase-activated dextrin-colistin conjugate to a lesser extent induced aggregatio

100 rimental evidence for the binding of dextrin-colistin conjugates and LPS and gives insight into the m

101 Dextrin-colistin conjugates have been developed with the aim of

102 tigated the in vitro ability of such dextrin-colistin conjugates to bind and modulate bacterial lipop

103 s insight into the mode of action of dextrin-colistin conjugates.

104 Gram-negative bacteria susceptible only to colistin (COS) are emerging causes of severe nosocomial

105 f patients receiving the EMA dose achieved a colistin Css,avg >/=1 mg/L, but the attainment rate was

106 For colistin Css,avg >/=2 mg/L, the attainment rates were 87

107 FDA- and EMA-approved daily doses to achieve colistin Css,avg of >/=0.5, >/=1, >/=2, and >/=4 mg/L we

108 approximately 65%-75% of patients achieved a colistin Css,avg of >/=1 mg/L with either set of recomme

109 Differences in attainment rates for a colistin Css,avg of >/=2 mg/L and >/=4 mg/L extended to

110 sis or septic shock may need relatively high colistin daily doses for efficacy against multidrug-resi

111 eatment, whereas the addition of aerosolized colistin did not affect overall mortality (odds ratio, 0

112 Resistance to the 10-microg colistin disk separated the Desulfovibrio species from m

113 Polymyxin B and colistin displayed a nearly identical spectrum of activi

114 udy to investigate the synergistic effect of colistin/doripenem combination on the metabolome of A. b

115 The primary objective was to determine if colistin dose (mg of colistin base activity/kg/day) inde

116 cluded evaluation for an association between colistin dose and 7-day mortality, 28-day mortality, and

117 lness and concomitant tigecyline use, higher colistin dose independently correlated with microbiologi

118 Higher colistin dose independently predicted microbiological su

119 The median colistin dose was also significantly higher among surviv

120 A significantly higher colistin dose was given to patients who developed AKI du

121 The median colistin dose was significantly higher in patients who a

122 However, no difference was observed in colistin dose when comparing survivors and nonsurvivors

123 Our primary exposure variable was colistin dose, dichotomized to high-dose vs other regime

124 morbidity, initial disease severity, loading colistin dose, polymicrobial infection, and primary infe

125 However, higher colistin doses may also precipitate worsening renal func

126 cohort, we found no association between high colistin dosing and all-cause mortality.

127 he purpose of this study was to determine if colistin dosing correlates with patient outcomes.

128 Optimizing colistin dosing should translate to improved patient out

129 However, colistin dosing varies greatly and the optimal regimen i

130 torrhea to receive hydrocortisone-bacitracin-colistin eardrops (76 children) or oral amoxicillin-clav

131 aumannii lacking lipid A were isolated after colistin exposure.

132 brosis in 2006-2012 and received intravenous colistin for >3 consecutive days or died during therapy

133 negative bacteremia treated with intravenous colistin for at least 72 hours.

134 e aimed to assess the safety and efficacy of colistin for the treatment of VAP.

135 ce with intravenous and aerosolized forms of colistin for the treatment of ventilator-associated pneu

136 ity to ampicillin, cefazolin, ciprofloxacin, colistin, gentamicin, meropenem, and tetracycline in com

137 Increasing use of colistin has led to resistance to this cationic antimicr

138 nsus on the most effective way to administer colistin has not yet been reached.

139 to three clinically relevant antimicrobials (colistin, imipenem or ciprofloxacin) by Transposon Direc

140 mpicin should not be routinely combined with colistin in clinical practice.

141 updated dose recommendations for intravenous colistin in patients with various degrees of renal funct

142 enables the highest nominal concentration of colistin in the test medium.

143 le if the efficacy and safety of aerosolized colistin in the treatment of ventilator-associated pneum

144 , this prodrug is converted back into active colistin in vitro within 24h.

145 nd A. baumannii and enhanced the activity of colistin in vivo against colistin-resistant P. aeruginos

146 CMS must be converted to colistin in vivo, but this occurs slowly and incompletel

147 ring murine infection, but in the absence of colistin, innate immune defences led to an increased fre

148 The polymixin colistin is a "last line" antibiotic against extensively

149 Colistin is a cationic antimicrobial peptide (CAMP) anti

150 Colistin is a key agent in treating infections caused by

151 s not reached, this study shows that inhaled colistin is a safe and effective treatment in adherent p

152 d directly as the active antibiotic, whereas colistin is administered as the inactive prodrug, colist

153 o effective against Gram-negative pathogens; colistin is advocated as the empirical drug of choice in

154 evidence from randomized trials, aerosolized colistin is associated with improved outcome in the trea

155 aumannii has risen rapidly in Vietnam, where colistin is becoming the drug of last resort for many in

156 Intravenous colistin is difficult to use because plasma concentratio

157 Background: Intravenous colistin is difficult to use because plasma concentratio

158 Colistin is increasingly used for the treatment of multi

159 Modified zone criteria for colistin (</=11 and >/=14 mm) and polymyxin B (</=10 and

160 tments, and more recently to carbapenems and colistin, make UTI a prime example of the antibiotic-res

161 Our results suggest that colistin may be as safe and as efficacious as standard a

162 Addition of rifampicin to colistin may be synergistic in vitro.

163 Colistin methanesulfonate (CMS) is the only prodrug of c

164 tin is administered as the inactive prodrug, colistin methanesulfonate (CMS).

165 With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resis

166 xture of antibiotics (kanamycin, gentamicin, colistin, metronidazole, and vancomycin) for 3 days.

167 Most of the Hafnia isolates had a colistin MIC of >/=2 mug/ml.

168 the disulphide isomerase DsbA increases the colistin MIC of laboratory E. coli.

169 Colistin MIC results obtained from the five methods were

170 t can occur when using different methods for colistin MIC testing and, in particular, to use caution

171 atically evaluated the available methods for colistin MIC testing in two phases.

172 ncreased tobramycin resistance but decreased colistin MICs and increased colistin susceptibility.

173 Zinc deprivation reduces colistin MICs in MCR-1-producing laboratory, environment

174 In phase I, colistin MICs were determined in 107 fresh clinical isol

175 enes essential for growth during exposure to colistin (n = 35), imipenem (n = 1) or ciprofloxacin (n

176 oxin A/B assays were routinely inoculated on colistin-naladixic acid agar plates, and S. aureus was i

177 te, dry, molar tooth appearance on anaerobic colistin nalidixic acid (CNA) agar which likely facilita

178 plated onto blood (blood agar plate [BAP]), colistin-nalidixic acid (CNA), and MacConkey agars in 5%

179 Staphylococcus isolates grown on blood agar, colistin-nalidixic acid agar (CNA), and mannitol salt ag

180 ies on sheep blood agar, chocolate agar, and colistin-nalidixic acid agar after 24 to 48 h of incubat

181 Colistin often remains the only therapeutic option.

182 Colistin, one of the last options to treat multidrug-res

183 ods to assist the therapeutic application of colistin or polymyxin B until disk diffusion test modifi

184 ritically ill patients receiving intravenous colistin or polymyxin B; it occurred in 60.4% and 41.8%,

185 relevant dosage regimens of polymyxin B and colistin over 96 h.

186 colistin vs 165 of 385 (42.9%) with low-dose colistin (P = .1).

187 ion of the lantibiotic paenibacillin and the colistin peptide polymyxin E1.

188 iologic eradication rate was observed in the colistin plus rifampicin arm (P = .034).

189 or susceptibility determination when testing colistin (polymyxin E) and polymyxin B, two polycationic

190 The resistance rate to colistin/polymyxin B was 16.1%.

191 Herein we describe a PEGylated colistin prodrug whereby the PEG is attached via a cleav

192 h high-dose colistin and 385 with lower-dose colistin regimens.

193 nant in colistin, returned to baseline after colistin removal and was dependent on the histidine kina

194 A high rate of colistin resistance (66%) emerged over a 10 month period

195 ssential gene not previously found linked to colistin resistance (dedA) restored colistin susceptibil

196 librium between expression of MCR-1-mediated colistin resistance and minimalizing toxicity and thus e

197 Reference colistin resistance determination as performed by broth

198 Acquisition of colistin resistance did not alter resistance to other an

199 Phylogenetic analysis suggested that colistin resistance emerged from a single progenitor col

200 Colistin resistance emerged in 18% (2/11) and 100% (3/3)

201 WGS demonstrated that mutational colistin resistance emerged three times during the outbr

202 In each of the four patients, colistin resistance evolved via mutations at the pmr loc

203 WGS found that three potential mechanisms of colistin resistance had emerged separately, two due to d

204 utational and plasmid-mediated mechanisms of colistin resistance have both been reported.

205 ovide insights into the in vivo evolution of colistin resistance in a series of XDR A. baumannii isol

206 entified over 30 genes involved in inducible colistin resistance in A. baumannii.

207 outbreaks of another concerning type of AMR, colistin resistance in Acinetobacter, in the Department

208 esistant Acinetobacter baumannii infections, colistin resistance is emerging.

209 Colistin resistance is of concern since it is increasing

210 Compared to their parent strains, high-level colistin resistance mutants (HLCRMs) show reduced fitnes

211 When an E coli strain, SHP45, possessing colistin resistance that could be transferred to another

212 luding 9 recent clinical isolates to develop colistin resistance through inactivation of the lipid A

213 tional mutations that may be associated with colistin resistance through novel resistance mechanisms.

214 data identified genomic evidence for stable colistin resistance undetected by clinical microbiologic

215 The emergence and clonal spread of colistin resistance was analysed in 40 epidemiologically

216 Colistin resistance was associated with point mutations

217 Colistin resistance was detected in 25/38 (65.8%) cases

218 m food animals in China, a major increase of colistin resistance was observed.

219 ation reduced the probability of reacquiring colistin resistance when subsequently challenged in vitr

220 To investigate the mechanism of colistin resistance, lipid A was subjected to matrix-ass

221 ddition of phosphoethanolamine accounted for colistin resistance.

222 ressor of phoPQ expression, thus suppressing colistin resistance.

223 ness cost preventing the evolution of stable colistin resistance.

224 regimens and may also limit the emergence of colistin resistance.

225 The mcr-1 gene confers transferable colistin resistance.

226 In this study we generated spontaneous colistin resistant progeny (up to >256 mug/mul) from fou

227 e II, 50 of these isolates, 10 of which were colistin resistant, were tested in parallel using BMD-T,

228 al assay recapitulated the classification as colistin resistant.

229 The treatment regimen for colistin-resistant A. baumannii infection associated wit

230 e modification of lipid A was present in all colistin-resistant A. baumannii isolates.

231 Colistin-resistant A. baumannii occurred almost exclusiv

232 tients with infection or colonization due to colistin-resistant A. baumannii were identified at a hos

233 Twenty patients with colistin-resistant A. baumannii were identified.

234 survival of most Gram-negative bacteria, but colistin-resistant Acinetobacter baumannii lacking lipid

235 thousand vs 1.6 per thousand; p = 0.05), and colistin-resistant Gram-negative bacilli (0.7 per thousa

236 ific AMR concerns, including carbapenem- and colistin-resistant gram-negative organisms, pose a clini

237 Moreover, colistin-resistant isolates already express the in vivo

238 Compared with colistin-susceptible isolates, colistin-resistant isolates displayed significantly enha

239 umannii infection prior to identification of colistin-resistant isolates.

240 iani et al. describe a sustained outbreak of colistin-resistant KPC-producing K. pneumoniae.

241 ced the activity of colistin in vivo against colistin-resistant P. aeruginosa.

242 , D-RR4 demonstrated potent activity against colistin-resistant strains of P. aeruginosa (isolated fr

243 An isolate with a lower-frequency colistin-resistant subpopulation similarly caused treatm

244 oQ, with onward transmission of two distinct colistin-resistant variants, resulting in two sub-clones

245 uring the outbreak, with transmission of two colistin-resistant variants.

246 10CFU/mL), while the gradual accumulation of colistin resulted in no bacterial killing.

247 tinct from persisters, became predominant in colistin, returned to baseline after colistin removal an

248 comparing adjunctive aerosolized versus i.v. colistin (seven observational cohort or case-control stu

249 Susceptibility testing for colistin should be considered for A. baumannii identifie

250 C8 was also synergistic with colistin, substantially improving survival compared to m

251 inked to colistin resistance (dedA) restored colistin susceptibility by reducing the minimum inhibito

252 r colonization with CRKp isolates tested for colistin susceptibility during the study period of Decem

253 In vitro evaluation of colistin susceptibility is fraught with complications, d

254 ine binding, or catalytic activity, restores colistin susceptibility of recombinant E. coli.

255 ined against which to compare the results of colistin susceptibility testing.

256 om July 2014 to October 2015 were tested for colistin susceptibility using agar dilution, and charact

257 as detected in 25/38 (65.8%) cases for which colistin susceptibility was tested.

258 ce but decreased colistin MICs and increased colistin susceptibility.

259 ions that could be attributed to the reduced colistin susceptibility.

260 ) that we hypothesise have a role in reduced colistin susceptibility.

261 stant progeny (up to >256 mug/mul) from four colistin susceptible Vietnamese isolates and one suscept

262 d CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection prior to ide

263 d CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection.

264 The colistin-susceptible and -resistant isolates from the sa

265 resistance emerged from a single progenitor colistin-susceptible isolate.

266 Compared with colistin-susceptible isolates, colistin-resistant isolat

267 as included once, at the time of their first colistin-tested CRKp positive culture.

268 ulation, leading to inefficacy of subsequent colistin therapy.

269 solates were longitudinally recovered during colistin therapy.

270 Triple drug combinations using colistin, tigecycline, and imipenem have recently been a

271 limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides).

272 eremia, treated with colistin-carbapenem and colistin-tigecycline combinations.

273 as use of parenteral colistin-carbapenem or colistin-tigecycline for at least 48 hours after onset o

274 te concentrations of combination therapy for colistin-tigecycline group was 18% and for colistin-carb

275 oints received standard combination therapy: colistin-tigecycline in 29 patients and colistin-carbape

276 day mortality was associated with the use of colistin-tigecycline in the subgroup with tigecycline mi

277 creased 14-day mortality was associated with colistin-tigecycline therapy given tigecycline minimum i

278 pital mortality rates for patients receiving colistin-tigecycline versus patients receiving colistin-

279 atients treated with colistin-carbapenem and colistin-tigecycline, respectively (p=0.03).

280 s of antibiotic exposure ranged from 1.4 for colistin to 4.9 for piperacillin-tazobactam.

281 as observed with the addition of aerosolized colistin to i.v. treatment, whereas the addition of aero

282 e bacterial processes required for intrinsic colistin tolerance in A. baumannii and underscore the im

283 Colistin tracking is a novel strategy for monitoring the

284 etobacter baumannii from patients undergoing colistin treatment, and upon subsequent drug withdrawal.

285 e evolved undetected in a patient undergoing colistin treatment, and was then transmitted to other ho

286 s improved after 26 weeks (P = 0.006) in the colistin versus placebo patients, respectively.

287 rials; examination of the relative merits of colistin versus polymyxin B for various types of infecti

288 were 50 of 144 (34.7%) deaths with high-dose colistin vs 165 of 385 (42.9%) with low-dose colistin (P

289 Treatment with colistin vs controls did not affect hospital mortality (

290 of Systematic Reviews for studies comparing colistin vs other antibiotics for treatment of VAP in pa

291 ptibility phenotype of DeltaphoP biofilms to colistin was comparable to that of P. aeruginosa biofilm

292 ng regimen of tigecycline plus gentamicin or colistin was effective for treating 24 of 26 (92%) Klebs

293 The efficacy of colistin was independent of study design (prospective OR

294 In medium with FBS, colistin was less efficacious in the 3-D cell model.

295 h severe sepsis or septic shock who received colistin was performed.

296 Colistin, which targets the lipid A domain of LPS/LOS to

297 susceptibility of P. aeruginosa biofilms to colistin, while inactivation of phoP and phoQ rendered b

298 ith increased resistance of P. aeruginosa to colistin, while overexpression of brlR resulted in incre

299 INTERPRETATION: In 2017, colistin will be formally banned from animal feeds in Ch

300 Upon colistin withdrawal, an ancestral susceptible strain out